State Street Corp Sells 78,806,661 Shares of Boston Scientific Corporation $BSX

State Street Corp trimmed its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 53.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,322,516 shares of the medical equipment provider’s stock after selling 78,806,661 shares during the quarter. State Street Corp owned approximately 4.64% of Boston Scientific worth $2,938,628,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Perigon Wealth Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth approximately $883,000. Y Intercept Hong Kong Ltd lifted its holdings in shares of Boston Scientific by 148.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after purchasing an additional 670,060 shares during the period. Wealthfront Advisers LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab lifted its holdings in shares of Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. purchased a new position in Boston Scientific in the 2nd quarter valued at $38,539,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 2.4%

Boston Scientific stock opened at $41.96 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. Boston Scientific Corporation has a 1-year low of $39.57 and a 1-year high of $101.91. The company has a market cap of $60.82 billion, a PE ratio of 17.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.60. The stock’s 50 day moving average price is $43.83 and its 200 day moving average price is $53.26.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. Boston Scientific’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 earnings per share. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Citigroup dropped their price objective on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, October 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Boston Scientific in a research note on Friday, October 2nd. Sanford C. Bernstein lowered their target price on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Needham & Company LLC lowered their target price on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, October 28th. Finally, Argus lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $61.43.

Read Our Latest Stock Report on BSX

About Boston Scientific

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Featured Articles

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.